Bolsa de Madrid - Data of ORYZON GENOMICS, S.A.

26/01/2022 17:37:19
Bid			Ask
Orders	Volume	Price	Price	Volume	Orders
1	2,824	3.0100	3.0350	1,000	1
3	2,951	3.0050	3.0450	2,500	1
5	6,550	3.0000	3.0500	23,598	6
2	2,543	2.9900	3.0700	5,589	2
1	2,112	2.9850	3.0800	500	1

1 year
5 years

Last pay

Type	Ex-date	Payment Date	Concept

Last split

Date	Equivalence

Last reverse split

Date	Equivalence

Last capital increase

Period	Proportion	Type
30/06/2020	15 x 100	Premium

	2022 until 26/01	2021	2020	2019	2018
Capitalisation * (thousands of euros)	159,985	143,270	185,720	127,296	84,702
Shares (x 1,000)	53,063	53,063	53,063	45,790	39,123
Period Close Price (euros)	3.0150	2.7000	3.5000	2.7800	2.1650
Period Last Price (euros)	3.0100	2.7000	3.5000	2.7800	2.1650
Period High Price (euros)	3.3500	4.3950	3.8950	4.4650	5.1800
Period Low Price (euros)	2.6900	2.6250	1.4760	2.1150	2.0450
Volume (thousands of shares)	4,191	61,454	91,825	78,113	95,258
Turnover (thousands of euros)	12,680	226,749	285,561	260,089	336,854

Profile

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

For more information, visit www.oryzon.com

Source: Issuing company.

27/01/2022 00:01:34

Research

Morningstar - Quantitative Report (9 July 2020 08:15) (64 KB)

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.